A., Dye J. implications for developing a broad range Rabbit Polyclonal to Cytochrome P450 2C8/9/18/19 of therapeutic and vaccine interventions against SARS-CoV-2 variants including Omicron sublineages. A rare human monoclonal antibody neutralizes all SARS-CoV-2 Omicron variants by targeting a conserved epitope around the RBD. INTRODUCTION The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory C-75 Trans syndrome coronavirus 2 (SARS-CoV-2) has resulted in roughly 552 million cases and 6 million deaths worldwide (for 20 min at room temperature, and the spike proteinCcontaining supernatant was collected. The supernatant was filtered and loaded onto prewashed His-Pur Ni-NTA (nickelCnitrilotriacetic acid) resin for affinity purification. The Ni-NTA resin was incubated with a spike trimerCcontaining supernatant for 2 hours on a shaker at room heat. Resin was washed with wash buffer made up of 25 mM imidazole, 6.7 mM NaH2PO4H2O, and 300 mM NaCl in PBS followed by spike protein elution in elution buffer made up of 235 mM imidazole, 6.7 mM NaH2PO4H2O, and C-75 Trans 300 mM NaCl in PBS. Eluted protein was dialyzed against PBS and was concentrated. The concentrated protein ran onto a Superose-6 Increase 10/300 column, and protein was eluted as trimeric spike was collected. The quality of the protein was evaluated by SDSCpolyacrylamide gel electrophoresis and by unfavorable stain EM. Unfavorable stain electron microscopy Spike protein was diluted to 0.05 mg/ml in PBS before grid preparation. A 3-l drop of diluted protein was applied to previously glow-discharged, carbon-coated grids for ~60 s, blotted and washed twice with water, stained with 0.75% uranyl formate, blotted, and air-dried. Between 30 and 50 images were collected on a Talos L120C microscope (Thermo Fisher Scientific) at 73,000 magnification and a pixel size of 1 1.97 ?. RELION 3.1 ((World Health Organiation, 2022); https://covid19.who.int/. 2. Kumar S., Chandele A., Sharma A., Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLOS Pathog. 17, e1009885 (2021). [PMC free article] [PubMed] [Google Scholar] 3. Bajpai P., Singh V., Chandele A., Kumar S., Broadly neutralizing antibodies to SARS-CoV-2 provide novel insights into the neutralization of variants and other human coronaviruses. Front. Cell. Infect. Microbiol. 12, 928279 (2022). [PMC free article] [PubMed] [Google Scholar] 4. Weisblum Y., Schmidt F., Zhang F., DaSilva J., Poston D., Lorenzi J. C., Muecksch F., Rutkowska M., Hoffmann H.-H., Michailidis E., Gaebler C., Agudelo M., Cho A., Wang Z., C-75 Trans Gazumyan A., Cipolla M., Luchsinger L., Hillyer C. D., Caskey M., Robbiani D. F., Rice C. M., Nussenzweig M. C., Hatziioannou T., Bieniasz P. D., Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312 (2020). [PMC free article] [PubMed] [Google Scholar] 5. Cheng V. C. C., Ip J. D., Chu A. W. H., Tam A. R., Chan W. M., Abdullah S. M. U., Chan B. P. C., Wong S. C., Kwan M. Y. W., Chua G. T., Ip P., Chan J. M. C., Lam B. H. S., To W. K., Chuang V. W. M., Yuen K. Y., Hung I. F. N., To K. K. W., Rapid spread of SARS-CoV-2 Omicron subvariant BA.2 in a single-source community outbreak. Clin. Infect. Dis. 75, e44Ce49 (2022). [PMC free article] [PubMed] [Google Scholar] 6. Edara V. V., Manning K. E., Ellis M., Lai L., Moore K. M., Foster S. L., Floyd K., Davis-Gardner M. E., Mantus G., Nyhoff L. E., Bechnak S., Alaaeddine G., Naji A., Samaha H., Lee M., Bristow L., Gagne M., Roberts-Torres J., Henry A. R., Godbole S.,.